GlassScriptPhysician profile
Fabian Rodriguez
NPI 1801855192
$1,095.04
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $745 · 2020: $110 · 2021: $134 · 2022: $106.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $244.60 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $184.36 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $163.79 | 2019-2022 | |
| Amgen INC. | $147.41 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $66.35 | 2019-2022 | |
| Pfizer INC. | $54.46 | 2019-2022 | |
| Neotract INC. | $40.92 | 2019 | |
| Boston Scientific Corporation | $39.32 | 2019 | |
| Abbvie INC. | $39.15 | 2019-2022 | |
| Daiichi Sankyo INC. | $37.22 | 2021-2022 | |
| Gilead Sciences, INC. | $15.22 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.67 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.31 | 2021 | |
| Hologic Sales and Service, LLC | $11.75 | 2021 | |
| Dynavax Technologies Corporation | $11.64 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $10.87 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fabian Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.